Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Bisphosphonates and atrial fibrillation risk: a final word

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: European Heart Journal
Personen und Körperschaften: Sousa, J, Lourenco, R, Lopes, J, Saleiro, C, De Campos, D, Lourenco, C, Goncalves, L
In: European Heart Journal, 42, 2021, Supplement_1
Format: E-Article
Sprache: Englisch
veröffentlicht:
Oxford University Press (OUP)
Schlagwörter:
Cardiology and Cardiovascular Medicine
author_facet Sousa, J
Lourenco, R
Lopes, J
Saleiro, C
De Campos, D
Lourenco, C
Goncalves, L
Sousa, J
Lourenco, R
Lopes, J
Saleiro, C
De Campos, D
Lourenco, C
Goncalves, L
author Sousa, J
Lourenco, R
Lopes, J
Saleiro, C
De Campos, D
Lourenco, C
Goncalves, L
spellingShingle Sousa, J
Lourenco, R
Lopes, J
Saleiro, C
De Campos, D
Lourenco, C
Goncalves, L
European Heart Journal
Bisphosphonates and atrial fibrillation risk: a final word
Cardiology and Cardiovascular Medicine
author_sort sousa, j
spelling Sousa, J Lourenco, R Lopes, J Saleiro, C De Campos, D Lourenco, C Goncalves, L 0195-668X 1522-9645 Oxford University Press (OUP) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1093/eurheartj/ehab724.2736 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Bisphosphonates (BPs) are widely prescribed drugs that decrease bone fracture risk in osteoporosis patients. Nevertheless, the class has been associated with a plethora of adverse effects, including incidental atrial fibrillation (AF). This epidemiologic link has, however, been met with skepticism by some authors.</jats:p> </jats:sec> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>To perform a meta-analysis aimed at ascertaining the extent to which BPs might increase the odds of AF.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We systematically searched MEDLINE, Embase, Web of Science, Cochrane Library and Google Scholar, from inception to the first of March, 2021, for randomized controlled trials comparing oral or intravenous BPs with placebo or a no-treatment control, in what concerns AF risk. In order to be included in the quantitative analysis, studies were required to feature a minimum patient follow-up of 6 months. De novo AF diagnoses served as the primary endpoint. Data related to individual BPs were further investigated separately, with respect to this outcome. Study-specific Mantel-Haenszel odds ratios (ORs) were pooled using traditional meta-analytic techniques, under a random-effects model.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>42 RCTs, encompassing 52.436 patients (32.071 randomized to BPs), were regarded as eligible for quantitative synthesis. Of note, 2 pooled analyses, one of 4 trials with ibandronate and the other of 6 trials with risedronate, were included. Individual BP representation may be depicted as follows: Alendronate, 23 trials, with 14.599 patients; Risedronate, 7 trials, with 15.350 patients; Zoledronic acid, 7 trials, with 13.059 patients; Ibandronate, 4 trials, with 8.754 patients; and Minedronate, 1 trial, with 674 patients. 748 de novo AF diagnoses were reported, in total. In the main analysis, BPs were not found to be significantly associated with an increase in AF odds (OR 1.10, 95% CI 0.95–1.28, P 0.21, i2 0%). As for individual BPs, Alendronate (OR 1.09, 95% CI 0.82–1.45, P 0.55, i2 0%), Risedronate (OR 0.81, 95% CI 0.35–1.86, P 0.61, i2 31%), Ibandronate (OR 0.89, 95% CI 0.52–1.52, P 0.67) and Minedronate (0 AF events reported, both in the active and in the control group) were also not shown to meaningfully enhance AF risk. On the contrary, Zoledronic acid utilization was associated with a significant, though small, increase in new AF cases (OR 1.29, 95% CI 1.01–1.64, P 0.04, i2 0%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The professed BP-driven increase in AF odds is not apparent in a fairly populated randomized setting. In fact, a barely significant increment in AF risk seems only to occur with the most potent BP (Zoledronic acid). Therefore, AF development concerns should not refrain doctors from prescribing this highly effective pharmacological class.</jats:p> </jats:sec> <jats:sec> <jats:title>Funding Acknowledgement</jats:title> <jats:p>Type of funding sources: None.</jats:p> </jats:sec> Bisphosphonates and atrial fibrillation risk: a final word European Heart Journal
doi_str_mv 10.1093/eurheartj/ehab724.2736
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ldXJoZWFydGovZWhhYjcyNC4yNzM2
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ldXJoZWFydGovZWhhYjcyNC4yNzM2
institution DE-Gla1
DE-Zi4
DE-15
DE-Rs1
DE-Pl11
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint Oxford University Press (OUP), 2021
imprint_str_mv Oxford University Press (OUP), 2021
issn 0195-668X
1522-9645
issn_str_mv 0195-668X
1522-9645
language English
mega_collection Oxford University Press (OUP) (CrossRef)
match_str sousa2021bisphosphonatesandatrialfibrillationriskafinalword
publishDateSort 2021
publisher Oxford University Press (OUP)
recordtype ai
record_format ai
series European Heart Journal
source_id 49
title Bisphosphonates and atrial fibrillation risk: a final word
title_unstemmed Bisphosphonates and atrial fibrillation risk: a final word
title_full Bisphosphonates and atrial fibrillation risk: a final word
title_fullStr Bisphosphonates and atrial fibrillation risk: a final word
title_full_unstemmed Bisphosphonates and atrial fibrillation risk: a final word
title_short Bisphosphonates and atrial fibrillation risk: a final word
title_sort bisphosphonates and atrial fibrillation risk: a final word
topic Cardiology and Cardiovascular Medicine
url http://dx.doi.org/10.1093/eurheartj/ehab724.2736
publishDate 2021
physical
description <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Bisphosphonates (BPs) are widely prescribed drugs that decrease bone fracture risk in osteoporosis patients. Nevertheless, the class has been associated with a plethora of adverse effects, including incidental atrial fibrillation (AF). This epidemiologic link has, however, been met with skepticism by some authors.</jats:p> </jats:sec> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>To perform a meta-analysis aimed at ascertaining the extent to which BPs might increase the odds of AF.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We systematically searched MEDLINE, Embase, Web of Science, Cochrane Library and Google Scholar, from inception to the first of March, 2021, for randomized controlled trials comparing oral or intravenous BPs with placebo or a no-treatment control, in what concerns AF risk. In order to be included in the quantitative analysis, studies were required to feature a minimum patient follow-up of 6 months. De novo AF diagnoses served as the primary endpoint. Data related to individual BPs were further investigated separately, with respect to this outcome. Study-specific Mantel-Haenszel odds ratios (ORs) were pooled using traditional meta-analytic techniques, under a random-effects model.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>42 RCTs, encompassing 52.436 patients (32.071 randomized to BPs), were regarded as eligible for quantitative synthesis. Of note, 2 pooled analyses, one of 4 trials with ibandronate and the other of 6 trials with risedronate, were included. Individual BP representation may be depicted as follows: Alendronate, 23 trials, with 14.599 patients; Risedronate, 7 trials, with 15.350 patients; Zoledronic acid, 7 trials, with 13.059 patients; Ibandronate, 4 trials, with 8.754 patients; and Minedronate, 1 trial, with 674 patients. 748 de novo AF diagnoses were reported, in total. In the main analysis, BPs were not found to be significantly associated with an increase in AF odds (OR 1.10, 95% CI 0.95–1.28, P 0.21, i2 0%). As for individual BPs, Alendronate (OR 1.09, 95% CI 0.82–1.45, P 0.55, i2 0%), Risedronate (OR 0.81, 95% CI 0.35–1.86, P 0.61, i2 31%), Ibandronate (OR 0.89, 95% CI 0.52–1.52, P 0.67) and Minedronate (0 AF events reported, both in the active and in the control group) were also not shown to meaningfully enhance AF risk. On the contrary, Zoledronic acid utilization was associated with a significant, though small, increase in new AF cases (OR 1.29, 95% CI 1.01–1.64, P 0.04, i2 0%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The professed BP-driven increase in AF odds is not apparent in a fairly populated randomized setting. In fact, a barely significant increment in AF risk seems only to occur with the most potent BP (Zoledronic acid). Therefore, AF development concerns should not refrain doctors from prescribing this highly effective pharmacological class.</jats:p> </jats:sec> <jats:sec> <jats:title>Funding Acknowledgement</jats:title> <jats:p>Type of funding sources: None.</jats:p> </jats:sec>
container_issue Supplement_1
container_start_page 0
container_title European Heart Journal
container_volume 42
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792320989676175370
geogr_code not assigned
last_indexed 2024-03-01T10:54:53.587Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Bisphosphonates+and+atrial+fibrillation+risk%3A+a+final+word&rft.date=2021-10-12&genre=article&issn=1522-9645&volume=42&issue=Supplement_1&jtitle=European+Heart+Journal&atitle=Bisphosphonates+and+atrial+fibrillation+risk%3A+a+final+word&aulast=Goncalves&aufirst=L&rft_id=info%3Adoi%2F10.1093%2Feurheartj%2Fehab724.2736&rft.language%5B0%5D=eng
SOLR
_version_ 1792320989676175370
author Sousa, J, Lourenco, R, Lopes, J, Saleiro, C, De Campos, D, Lourenco, C, Goncalves, L
author_facet Sousa, J, Lourenco, R, Lopes, J, Saleiro, C, De Campos, D, Lourenco, C, Goncalves, L, Sousa, J, Lourenco, R, Lopes, J, Saleiro, C, De Campos, D, Lourenco, C, Goncalves, L
author_sort sousa, j
container_issue Supplement_1
container_start_page 0
container_title European Heart Journal
container_volume 42
description <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Bisphosphonates (BPs) are widely prescribed drugs that decrease bone fracture risk in osteoporosis patients. Nevertheless, the class has been associated with a plethora of adverse effects, including incidental atrial fibrillation (AF). This epidemiologic link has, however, been met with skepticism by some authors.</jats:p> </jats:sec> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>To perform a meta-analysis aimed at ascertaining the extent to which BPs might increase the odds of AF.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We systematically searched MEDLINE, Embase, Web of Science, Cochrane Library and Google Scholar, from inception to the first of March, 2021, for randomized controlled trials comparing oral or intravenous BPs with placebo or a no-treatment control, in what concerns AF risk. In order to be included in the quantitative analysis, studies were required to feature a minimum patient follow-up of 6 months. De novo AF diagnoses served as the primary endpoint. Data related to individual BPs were further investigated separately, with respect to this outcome. Study-specific Mantel-Haenszel odds ratios (ORs) were pooled using traditional meta-analytic techniques, under a random-effects model.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>42 RCTs, encompassing 52.436 patients (32.071 randomized to BPs), were regarded as eligible for quantitative synthesis. Of note, 2 pooled analyses, one of 4 trials with ibandronate and the other of 6 trials with risedronate, were included. Individual BP representation may be depicted as follows: Alendronate, 23 trials, with 14.599 patients; Risedronate, 7 trials, with 15.350 patients; Zoledronic acid, 7 trials, with 13.059 patients; Ibandronate, 4 trials, with 8.754 patients; and Minedronate, 1 trial, with 674 patients. 748 de novo AF diagnoses were reported, in total. In the main analysis, BPs were not found to be significantly associated with an increase in AF odds (OR 1.10, 95% CI 0.95–1.28, P 0.21, i2 0%). As for individual BPs, Alendronate (OR 1.09, 95% CI 0.82–1.45, P 0.55, i2 0%), Risedronate (OR 0.81, 95% CI 0.35–1.86, P 0.61, i2 31%), Ibandronate (OR 0.89, 95% CI 0.52–1.52, P 0.67) and Minedronate (0 AF events reported, both in the active and in the control group) were also not shown to meaningfully enhance AF risk. On the contrary, Zoledronic acid utilization was associated with a significant, though small, increase in new AF cases (OR 1.29, 95% CI 1.01–1.64, P 0.04, i2 0%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The professed BP-driven increase in AF odds is not apparent in a fairly populated randomized setting. In fact, a barely significant increment in AF risk seems only to occur with the most potent BP (Zoledronic acid). Therefore, AF development concerns should not refrain doctors from prescribing this highly effective pharmacological class.</jats:p> </jats:sec> <jats:sec> <jats:title>Funding Acknowledgement</jats:title> <jats:p>Type of funding sources: None.</jats:p> </jats:sec>
doi_str_mv 10.1093/eurheartj/ehab724.2736
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9ldXJoZWFydGovZWhhYjcyNC4yNzM2
imprint Oxford University Press (OUP), 2021
imprint_str_mv Oxford University Press (OUP), 2021
institution DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 0195-668X, 1522-9645
issn_str_mv 0195-668X, 1522-9645
language English
last_indexed 2024-03-01T10:54:53.587Z
match_str sousa2021bisphosphonatesandatrialfibrillationriskafinalword
mega_collection Oxford University Press (OUP) (CrossRef)
physical
publishDate 2021
publishDateSort 2021
publisher Oxford University Press (OUP)
record_format ai
recordtype ai
series European Heart Journal
source_id 49
spelling Sousa, J Lourenco, R Lopes, J Saleiro, C De Campos, D Lourenco, C Goncalves, L 0195-668X 1522-9645 Oxford University Press (OUP) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1093/eurheartj/ehab724.2736 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Bisphosphonates (BPs) are widely prescribed drugs that decrease bone fracture risk in osteoporosis patients. Nevertheless, the class has been associated with a plethora of adverse effects, including incidental atrial fibrillation (AF). This epidemiologic link has, however, been met with skepticism by some authors.</jats:p> </jats:sec> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>To perform a meta-analysis aimed at ascertaining the extent to which BPs might increase the odds of AF.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We systematically searched MEDLINE, Embase, Web of Science, Cochrane Library and Google Scholar, from inception to the first of March, 2021, for randomized controlled trials comparing oral or intravenous BPs with placebo or a no-treatment control, in what concerns AF risk. In order to be included in the quantitative analysis, studies were required to feature a minimum patient follow-up of 6 months. De novo AF diagnoses served as the primary endpoint. Data related to individual BPs were further investigated separately, with respect to this outcome. Study-specific Mantel-Haenszel odds ratios (ORs) were pooled using traditional meta-analytic techniques, under a random-effects model.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>42 RCTs, encompassing 52.436 patients (32.071 randomized to BPs), were regarded as eligible for quantitative synthesis. Of note, 2 pooled analyses, one of 4 trials with ibandronate and the other of 6 trials with risedronate, were included. Individual BP representation may be depicted as follows: Alendronate, 23 trials, with 14.599 patients; Risedronate, 7 trials, with 15.350 patients; Zoledronic acid, 7 trials, with 13.059 patients; Ibandronate, 4 trials, with 8.754 patients; and Minedronate, 1 trial, with 674 patients. 748 de novo AF diagnoses were reported, in total. In the main analysis, BPs were not found to be significantly associated with an increase in AF odds (OR 1.10, 95% CI 0.95–1.28, P 0.21, i2 0%). As for individual BPs, Alendronate (OR 1.09, 95% CI 0.82–1.45, P 0.55, i2 0%), Risedronate (OR 0.81, 95% CI 0.35–1.86, P 0.61, i2 31%), Ibandronate (OR 0.89, 95% CI 0.52–1.52, P 0.67) and Minedronate (0 AF events reported, both in the active and in the control group) were also not shown to meaningfully enhance AF risk. On the contrary, Zoledronic acid utilization was associated with a significant, though small, increase in new AF cases (OR 1.29, 95% CI 1.01–1.64, P 0.04, i2 0%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The professed BP-driven increase in AF odds is not apparent in a fairly populated randomized setting. In fact, a barely significant increment in AF risk seems only to occur with the most potent BP (Zoledronic acid). Therefore, AF development concerns should not refrain doctors from prescribing this highly effective pharmacological class.</jats:p> </jats:sec> <jats:sec> <jats:title>Funding Acknowledgement</jats:title> <jats:p>Type of funding sources: None.</jats:p> </jats:sec> Bisphosphonates and atrial fibrillation risk: a final word European Heart Journal
spellingShingle Sousa, J, Lourenco, R, Lopes, J, Saleiro, C, De Campos, D, Lourenco, C, Goncalves, L, European Heart Journal, Bisphosphonates and atrial fibrillation risk: a final word, Cardiology and Cardiovascular Medicine
title Bisphosphonates and atrial fibrillation risk: a final word
title_full Bisphosphonates and atrial fibrillation risk: a final word
title_fullStr Bisphosphonates and atrial fibrillation risk: a final word
title_full_unstemmed Bisphosphonates and atrial fibrillation risk: a final word
title_short Bisphosphonates and atrial fibrillation risk: a final word
title_sort bisphosphonates and atrial fibrillation risk: a final word
title_unstemmed Bisphosphonates and atrial fibrillation risk: a final word
topic Cardiology and Cardiovascular Medicine
url http://dx.doi.org/10.1093/eurheartj/ehab724.2736